156 related articles for article (PubMed ID: 32439931)
1. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
Kostaras E; Kaserer T; Lazaro G; Heuss SF; Hussain A; Casado P; Hayes A; Yandim C; Palaskas N; Yu Y; Schwartz B; Raynaud F; Chung YL; Cutillas PR; Vivanco I
Br J Cancer; 2020 Aug; 123(4):542-555. PubMed ID: 32439931
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
[TBL] [Abstract][Full Text] [Related]
3. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
[TBL] [Abstract][Full Text] [Related]
4. ATP-competitive and allosteric inhibitors induce differential conformational changes at the autoinhibitory interface of Akt1.
Shaw AL; Parson MAH; Truebestein L; Jenkins ML; Leonard TA; Burke JE
Structure; 2023 Mar; 31(3):343-354.e3. PubMed ID: 36758543
[TBL] [Abstract][Full Text] [Related]
5. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
Blake JF; Xu R; Bencsik JR; Xiao D; Kallan NC; Schlachter S; Mitchell IS; Spencer KL; Banka AL; Wallace EM; Gloor SL; Martinson M; Woessner RD; Vigers GP; Brandhuber BJ; Liang J; Safina BS; Li J; Zhang B; Chabot C; Do S; Lee L; Oeh J; Sampath D; Lee BB; Lin K; Liederer BM; Skelton NJ
J Med Chem; 2012 Sep; 55(18):8110-27. PubMed ID: 22934575
[TBL] [Abstract][Full Text] [Related]
6. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Layton ME; Bilodeau MT
Curr Cancer Drug Targets; 2008 Feb; 8(1):7-18. PubMed ID: 18288939
[TBL] [Abstract][Full Text] [Related]
7. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
Wang P; Zhang L; Hao Q; Zhao G
Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
[TBL] [Abstract][Full Text] [Related]
8. Microsecond molecular dynamics simulations provide insight into the ATP-competitive inhibitor-induced allosteric protection of Akt kinase phosphorylation.
Mou L; Cui T; Liu W; Zhang H; Cai Z; Lu S; Gao G
Chem Biol Drug Des; 2017 May; 89(5):723-731. PubMed ID: 27797456
[TBL] [Abstract][Full Text] [Related]
9. FCX-146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second-generation arylidene indanone scaffold.
Balasubramaniam M; Lakkaniga NR; Dera AA; Fayi MA; Abohashrh M; Ahmad I; Chandramoorthy HC; Nalini G; Rajagopalan P
Biotechnol Appl Biochem; 2021 Feb; 68(1):82-91. PubMed ID: 32067263
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors in AKTion: ATP-competitive vs allosteric.
Lazaro G; Kostaras E; Vivanco I
Biochem Soc Trans; 2020 Jun; 48(3):933-943. PubMed ID: 32453400
[TBL] [Abstract][Full Text] [Related]
12. Covalent-Allosteric Kinase Inhibitors.
Weisner J; Gontla R; van der Westhuizen L; Oeck S; Ketzer J; Janning P; Richters A; Mühlenberg T; Fang Z; Taher A; Jendrossek V; Pelly SC; Bauer S; van Otterlo WA; Rauh D
Angew Chem Int Ed Engl; 2015 Aug; 54(35):10313-6. PubMed ID: 26110718
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS
Cancer Res; 2013 Apr; 73(8):2574-86. PubMed ID: 23436801
[TBL] [Abstract][Full Text] [Related]
15. Recent progress towards clinically relevant ATP-competitive Akt inhibitors.
Huck BR; Mochalkin I
Bioorg Med Chem Lett; 2017 Jul; 27(13):2838-2848. PubMed ID: 28506751
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
Dumble M; Crouthamel MC; Zhang SY; Schaber M; Levy D; Robell K; Liu Q; Figueroa DJ; Minthorn EA; Seefeld MA; Rouse MB; Rabindran SK; Heerding DA; Kumar R
PLoS One; 2014; 9(6):e100880. PubMed ID: 24978597
[TBL] [Abstract][Full Text] [Related]
17. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Najafov A; Shpiro N; Alessi DR
Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
[TBL] [Abstract][Full Text] [Related]
18. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
19. Cellular model system to dissect the isoform-selectivity of Akt inhibitors.
Quambusch L; Depta L; Landel I; Lubeck M; Kirschner T; Nabert J; Uhlenbrock N; Weisner J; Kostka M; Levy LM; Schultz-Fademrecht C; Glanemann F; Althoff K; Müller MP; Siveke JT; Rauh D
Nat Commun; 2021 Sep; 12(1):5297. PubMed ID: 34489430
[TBL] [Abstract][Full Text] [Related]
20. Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors.
Savill KMZ; Lee BB; Oeh J; Lin J; Lin E; Chung WJ; Young A; Chen W; Miś M; Mesh K; Eastham J; Gnad F; Jiang Z; Stawiski EW; Haley B; Daemen A; Wang X; Koeppen H; Modrusan Z; Martin SE; Sampath D; Lin K
Nat Commun; 2022 Apr; 13(1):2057. PubMed ID: 35440108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
